Icatibant: Indication, Dosage, Side Effect, Precaution

This information is not country-specific. Please refer to the Malaysia prescribing information.

Generic Medicine Info

Indications and Dosage

Subcutaneous
Hereditary angioedema

Adult: Patient w/ C1-esterase inhibitor deficiency: 30 mg as a single dose during acute attack. May repeat dose 6 hrly if response is inadequate or symptoms recur. Max: 90 mg daily.

Special Precautions

Patient w/ acute ischaemic heart disease, unstable angina pectoris, history or recently had a stroke.

Adverse Reactions

Significant: Airway obstruction.
Nervous: Dizziness, headache.
GI: Nausea.
Hepatic: Increased serum transaminase.
Dermatologic: Rash, erythema, pruritus.
Others: Pyrexia, inj site reaction (e.g. burning, swelling, itching, warm sensation, pain).

Pregnancy Category (US FDA)

SC: C

Patient Counseling Information

This drug may cause dizziness, if affected, do not drive or operate machinery.

Monitoring Parameters

Monitor symptom relief; laryngeal symptoms or airway obstruction.

Drug Interactions

Decreased antihypertensive effect of ACE inhibitors.

Action

Description: Icatibant, a selective bradykinin antagonist, inhibits bradykinin from binding B2 receptor which causes vasodilation, localised swelling, inflammation and acute pain and thereby relieves the symptoms of acute attack.
Onset: 50% decrease in symptoms: Approx 2 hr.
Duration: Approx 6 hr.
Pharmacokinetics:
Absorption: Bioavailability: Approx 97%. Time to peak plasma concentration: 0.75 hr.
Distribution: Volume of distribution: 20-25 L. Plasma protein binding: 44%.
Metabolism: Extensively metabolised by proteolytic enzymes to inactive metabolites.
Excretion: Mainly via urine, <10% as unchanged drug. Elimination half-life 1-1.8 hr.

Chemical Structure

Storage

Store between 2-25°C. Follow applicable procedures for receiving, handling, admin, and disposal. Wear gloves during receiving, unpacking, and placing in storage.

MIMS Class

Other Cardiovascular Drugs

ATC Classification

B06AC02 - icatibant ; Belong to the class of drugs used in the treatment of hereditary angioedema.

References

Anon. Icatibant. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 05/12/2017.

Buckingham R (ed). Icatibant Acetate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/12/2017.

Firazyr Injection, Solution (Shire US Manufacturing Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 05/12/2017.

Joint Formulary Committee. Icatibant. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/12/2017.

McEvoy GK, Snow EK, Miller J et al (eds). Icatibant Acetate. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 05/12/2017.

Disclaimer: This information is independently developed by MIMS based on Icatibant from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com